Form 4 for OKUR OnKure Therapeutics, Inc.
Accepted 2023-08-29 00:00:00 ET · period of report 2023-08-28 · accession 0001209191-23-047626 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-08-29 | 2023-08-28 | OKUR | Hall Ashley | Chief Development Off | S - Sale+OE | $6.28 | -15.6K | 39.6K | -28% | -$98.1K |
| D | 2023-08-29 | 2023-08-28 | OKUR | Hall Ashley | Chief Development Off | M - OptEx | $1.80 | +15.6K | 55.2K | +39% | +$28.1K |
| D | 2023-08-29 | 2023-08-28 | OKUR | Hall Ashley | Chief Development Off | M - OptEx | $0.00 | -15.6K | 109.4K | -12% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-28 | S | D | 15,625 | $6.28 | 39,600 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.24 to $6.44, inclusive. The reporting person undertakes to provide any security holder of Reneo Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
| 2 | Common | Common Stock | 2023-08-28 | M | A | 15,625 | $1.80 | 55,225 | D | — | — | (F1) Includes 4,000 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on June 8, 2023. |
| 3 | Derivative | Stock option (right to buy) | 2023-08-28 | M | D | 15,625 | $0.00 | 109,375 | D | $1.80 · — to 2032-12-08 | 15,625 Common Stock | (F3) The shares vest in a series of 16 equal quarterly installments measured from December 9, 2022 subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date. |